Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS - Full Text View

Purpose

The primary objective of this study is to determine whether combination treatment (adding methylprednisolone to Avonex) reduces progression of disability over 4 years compared to Avonex alone. The study will also investigate whether combination therapy has any impact on the incidence of relapse and brain atrophy as measured by MRI.

Condition	Intervention	Phase
Relapsing-remitting Multiple Sclerosis	Drug: Interferon-beta-1a (Avonex) plus methylprednisolone	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Investigator) Primary Purpose: Treatment
Official Title:	A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Investigating Methylprednisolone in Combination With Interferon-beta-1a for the Treatment of Patients With Relapsing-remitting Multiple Sclerosis

Resource links provided by NLM:

Genetics Home Reference related topics: multiple sclerosis

MedlinePlus related topics: Multiple Sclerosis

Drug Information available for: Prednisolone Prednisolone acetate Methylprednisolone acetate Methylprednisolone Prednisolone sodium phosphate Prednisolone phosphate Prednisolone sodium succinate Methylprednisolone sodium succinate Interferon Interferon beta Interferon beta-1a Avonex

U.S. FDA Resources

Further study details as provided by Biogen:

Primary Outcome Measures:

To estimate the effect interferon-beta-1a in combination with methylprednisolone vs interferon-beta-1a in combination with placebo on the time to onset of disability progression sustained over at least 6 months based on change from randomization in EDSS [ Time Frame: 4 years ]


Enrollment:	345
Study Start Date:	January 2003
Study Completion Date:	November 2008
Primary Completion Date:	November 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1 interferon-beta-1a in combination with methylprednisolone	Drug: Interferon-beta-1a (Avonex) plus methylprednisolone oral administration given on 3 consecutive days, monthly as described in protocol. Other Name: Avonex
Placebo Comparator: 2 interferon-beta-1a in combination with placebo	Drug: Interferon-beta-1a (Avonex) plus methylprednisolone oral administration given on 3 consecutive days, monthly as described in protocol. Other Name: Avonex

Detailed Description:

Approximately 340 therapy-naïve MS patients with relapsing-remitting form of the disease will be randomized to receive Avonex alone or Avonex plus methylprednisolone (MP). Patients will receive MP as 500 mg po for 3 days every month or matching placebo. The patients are followed on a 3-monthly basis for 4 years with disability as the primary parameter of efficacy over that time.

Eligibility


Ages Eligible for Study:	18 Years to 55 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Informed consent
Relapsing remitting MS according to Poser criteria or McDonell criteria and naïve to therapy
Disability EDSS score of 4.0 or less at baseline
Clinical activity as defined by at least one relapse in the last year

Exclusion Criteria:

Relapse in the month prior to enrolment
Treatment with immunosuppressive drugs for MS
History of major depression
Former severe reactions to corticosteroids
Pregnant women
Diabetes mellitus, and drug or alcohol dependency
Known or suspected allergy to trial products

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00168766

Locations


Belgium
CUB Hôpital Erasme
Bruxelles, Belgium
Denmark
Coordinating Research Site
Copenhagen, Denmark
Rigshospitalet
Skleroseklinikken, Denmark
Finland
Tampereen yliopistollinen sairaala - Neurologian klinikka
Tampere, Finland
Netherlands
Stichting MS Centrum
Nijemegen, Netherlands
Norway
Ullevål Universitetssykehus
Oslo, Norway
Sweden
Neurologkliniken
Stockholm, Sweden
Switzerland
Kantonspital
St. Gallen, Switzerland
United Kingdom
Queens Medical Centre - Division of Neurology
Nottingham, United Kingdom, Ng72uh

Sponsors and Collaborators

Biogen

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Ravnborg M, Sørensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, Bartholomé E, Constantinescu CS, Beer K, Garde E, Sperling B. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol. 2010 Jul;9(7):672-80. doi: 10.1016/S1474-4422(10)70132-0. Epub 2010 Jun 9. Erratum in: Lancet Neurol. 2010 Aug;9(8):759.


Responsible Party:	Biogen Idec MD, Nordic Medical Director, Biogen Idec International
ClinicalTrials.gov Identifier:	NCT00168766 History of Changes
Obsolete Identifiers:	NCT00492180
Other Study ID Numbers:	NOR-03-01 Mecombin
Study First Received:	September 13, 2005
Last Updated:	September 12, 2013

Keywords provided by Biogen:


Combination therapy for multiple sclerosis

Additional relevant MeSH terms:


Sclerosis Multiple Sclerosis Multiple Sclerosis, Relapsing-Remitting Pathologic Processes Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System Nervous System Diseases Demyelinating Diseases Autoimmune Diseases Immune System Diseases Interferons Methylprednisolone Hemisuccinate Prednisolone Interferon-beta Interferon beta-1a	Prednisolone acetate Methylprednisolone acetate Methylprednisolone Prednisolone hemisuccinate Prednisolone phosphate Antineoplastic Agents Antiviral Agents Anti-Infective Agents Anti-Inflammatory Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Glucocorticoids

ClinicalTrials.gov processed this record on July 24, 2017